Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721407 | 0.83 | EGLN2 (0.37) | EGLN2LRRK2SMN1; SMN2KDM4EAR | |
| SCHEMBL13058728 | 0.79 | ALDH1A1 (0.36) | CDK1KDRROCK2ROCK1CDC42BPA | |
| SCHEMBL27270574 | 0.79 | AR (0.38) | CDK1KDRAAK1ROCK2ROCK1 | |
| SCHEMBL21709820 | 0.78 | ALDH1A1 (0.35) | CDK1KDRAAK1ROCK2ROCK1 | |
| SCHEMBL22096839 | 0.78 | CDK1 (0.35) | CDK1KDRAAK1ROCK2ROCK1 | |
| SCHEMBL13058508 | 0.78 | AR (0.39) | CDK1KDRLRRK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2838568 | 0.75 | AAK1 (0.39) | EGLN2AAK1ROCK2ROCK1CDC42BPA | |
| SCHEMBL19745530 | 0.74 | EGLN2 (0.41) | EGLN2ROCK2ROCK1CDC42BPACDC42BPB | |
| SCHEMBL21718451 | 0.74 | CXCR2 (0.30) | CXCR2 | |
| SCHEMBL13058512 | 0.74 | CDK1 (0.31) | CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | EGLN2 281/4885CDK1 3645/4885KDR 1432/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | EGLN2 281/4885CDK1 3645/4885KDR 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.